Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer
Background. Although therapeutic advances have led to enhanced survival in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, detection of residual disease remains challenging. Here, we examine two approved anti-HER2 monoclonal antibodies (mAbs), trastuzumab and pe...
Saved in:
Main Authors: | Solmaz AghaAmiri, Jo Simien, Alastair M. Thompson, Julie Voss, Sukhen C. Ghosh, Servando Hernandez Vargas, Sarah Kim, Ali Azhdarinia, Hop S. Tran Cao |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-01-01
|
Series: | Molecular Imaging |
Online Access: | http://dx.doi.org/10.1155/2021/5540569 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
by: Hanghang Ma, et al.
Published: (2025-02-01) -
Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer
by: Riqing Huang, et al.
Published: (2025-01-01) -
Comparative Study between Quantitative Digital Image Analysis and Fluorescence In Situ Hybridization of Breast Cancer Equivocal HER2 2+ Cases
by: E. Ayad, et al.
Published: (2014-01-01) -
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01) -
The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
by: Sanaa Gamrani, et al.
Published: (2023-01-01)